Difference between revisions of "Vorinostat (Zolinza)"
m |
|||
Line 12: | Line 12: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
− | |||
*[[Chronic myelomonocytic leukemia]] | *[[Chronic myelomonocytic leukemia]] | ||
*[[Cutaneous T-cell lymphoma]] | *[[Cutaneous T-cell lymphoma]] | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
− | |||
*[[Marginal zone lymphoma]] | *[[Marginal zone lymphoma]] | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
*[[Myelodysplastic syndrome]] | *[[Myelodysplastic syndrome]] | ||
+ | |||
+ | ==Diseases for which it was used== | ||
+ | *[[Acute myeloid leukemia - historical|Acute myeloid leukemia]] | ||
+ | *[[Hodgkin lymphoma - historical|Hodgkin lymphoma]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Line 35: | Line 37: | ||
[[Category:HDAC inhibitors]] | [[Category:HDAC inhibitors]] | ||
− | |||
[[Category:Chronic myelomonocytic leukemia medications]] | [[Category:Chronic myelomonocytic leukemia medications]] | ||
[[Category:Cutaneous T-cell lymphoma medications]] | [[Category:Cutaneous T-cell lymphoma medications]] | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
− | |||
[[Category:Marginal zone lymphoma medications]] | [[Category:Marginal zone lymphoma medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:Myelodysplastic syndrome medications]] | [[Category:Myelodysplastic syndrome medications]] | ||
+ | |||
+ | [[Category:Acute myeloid leukemia medications (historic)]] | ||
+ | [[Category:Hodgkin lymphoma medications (historic)]] | ||
[[Category:FDA approved in 2006]] | [[Category:FDA approved in 2006]] |
Revision as of 02:11, 29 April 2022
General information
Class/mechanism: Histone deacetylase (HDAC) inhibitor. Vorinostat inhibits histone deacetylases HDAC1, HDAC2, and HDAC3 (Class I), as well as HDAC6 (Class II). HDACs normally catalyze removal of acetyl groups from acetylated lysine residues in histones and non-histone proteins, which helps to regulate gene expression. Inhibition of histone deacetylases results in hyperacetylation of histones and modulates gene expression by creating an open chromatin state that leads to expression of previously silenced genes. Although the mechanism of action is not fully understood, inhibiting HDACs has been observed to result in cell cycle arrest and apoptosis of cancer cells.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Vorinostat (Zolinza) manufacturer's patient drug information[4]
- Vorinostat (Zolinza) patient drug information (Chemocare)[5]
- Vorinostat (Zolinza) patient drug information (UpToDate)[6]
Diseases for which it is used
- Chronic myelomonocytic leukemia
- Cutaneous T-cell lymphoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Marginal zone lymphoma
- Multiple myeloma
- Myelodysplastic syndrome
Diseases for which it was used
History of changes in FDA indication
- 10/06/2006: Initial FDA approval: treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.
Also known as
- Brand name: Zolinza
References
- ↑ 1.0 1.1 Vorinostat (Zolinza) package insert
- ↑ Vorinostat (Zolinza) package insert (locally hosted backup)
- ↑ Zolinza manufacturer's site
- ↑ Vorinostat (Zolinza) manufacturer's patient drug information
- ↑ Vorinostat (Zolinza) patient drug information (Chemocare)
- ↑ Vorinostat (Zolinza) patient drug information (UpToDate)
- Drugs
- Oral medications
- HDAC inhibitors
- Chronic myelomonocytic leukemia medications
- Cutaneous T-cell lymphoma medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Marginal zone lymphoma medications
- Multiple myeloma medications
- Myelodysplastic syndrome medications
- Acute myeloid leukemia medications (historic)
- Hodgkin lymphoma medications (historic)
- FDA approved in 2006